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Summary Serum samples from 62 patients with seminoma were assayed for placental alkaline phosphatase-
like activity using the monoclonal antibody H17 E2, in order to evaluate its utility as a serum tumour marker.
Fifteen of 16 patients (94%) with active seminoma had elevated serum PLAP levels. Sixteen of 46 (35%) of
patients considered to be in remission had elevated PLAP levels (false positive rate 35%). Fifteen false positive
results were considered attributable to concomitant smoking, and if these patients are excluded, only one false
positive case was detected. In 7 out of 7 patients sequential PLAP assays reflected clinical response to
treatment.
Placental alkaline phosphatase (PLAP) is an
isozyme of the alkaline phosphatase group of
enzymes and is normally synthesized in the
placental syncitiotrophoblast after the twelfth week
of pregnancy when it is shed into the maternal
circulation (Fishman et al., 1968a, Sussman et al.,
1968). The enzyme is a dimer and is polymorphic,
with three common alleles responsible for 97.5% of
the placental phenotypes (Harris, 1980).
Placental alkaline phosphatase was recognised as
an oncofoetal antigen by Fishman et al. (1968b)
originally in the serum of a patient (Regan) with a
squamous cell carcinoma of the lung. It has been
found in the serum of certain patients with tumours
of the testis (Nathanson & Fishman, 1971;
Holmgren et al., 1978; Wahren et al., 1979; Lange
et al., 1982), tumours of the ovary and uterus
(Nathanson & Fishman, 1971; Cadeau et al., 1974;
Nishiyama et al., 1980), and a range of other
malignancies (Fishman & Stolbach, 1979).
Nakayama et al. (1970) described a patient
(Nagao) who had elevated serum levels of a variant
ioszyme of placental alkaline phosphatase that
differed from the Regan subtype in being inhibited
by L-leuchine. The pattern of expression of these
isozymes varies in different tumour types (Inglis et
al., 1973). Variants of the placental alkaline
phosphatase can be distinguished by monoclonal
antibodies (Millan et al., 1982; Millan & Stigbrand,
1983).
In testicular tumours raised serum levels of
PLAP have been associated particularly with
seminomatous components (Wahren et al., 1979;
Correspondence: A. Horwich, The Royal Marsden
Hospital, Downs Road, Sutton, Surrey, SM2 5PT.
Received 7 September 1984; and in revised from 28
December 1984.
Lange et al., 1982; Javadpour, 1983; Jeppsson et
al., 1983). This study reports on the correlation
between serum PLAP levels and disease status in 62
patients with seminoma whose serum was analyzed
for PLAP-like activity using the monoclonal
antibody H17 E2. This antibody had been raised
against term placental membranes (Travers &
Bodmer, 1984; McLaughlin et al., 1984). Our data
complement and extend results reported in an
accompanying paper (Tucker et al., 1985), and in
particular are focused on the role of this assay in
the management of seminoma and on interpretive
difflculties caused by the effects of smoking.
Patients and methods
Serum samples from 62 patients whose tumour
biopsies had revealed pure seminoma were referred
to the Imperial Cancer Research Fund Laboratories
for analysis of PLAP-like activity by immune-
assisted enzyme assay (ILEA) as described by
Tucker et al. (1985) in an accompanying article.
Results of the PLAP assay are presented in OD
units. For conversion to International units see
calibration curves in Tucker et al (1985). Serum
had been collected since 1977 and stored at -20°C.
The histopathological diagnosis of pure seminoma
was confirmed by review in all cases in the
Department of Histopathology, The Royal
Marsden Hospital, and the assessment and
management of these patients was as previously
reported (Peckham, 1981; Ball et al., 1982). The
serum samples were obtained originally during the
following clinical situations: 16 patients pre-
treatment with unequivocal evidence of metastatic
seminoma; 46 patients who have remained clear of
malignant disease for 18 months to 5 years, (mean
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33 months). Additionally, in 7 of 16 patients
treated with chemotherapy for metastatic disease
sequential serum samples were available to
investigate the correlation of changes in serum
PLAP level with disease activity.
Results
Figure I shows serum levels of PLAP activity in 62
evaluable seminoma patients. Following studies by
Tucker et al. (1985) on nonsmokers we have taken
the upper level of normal PLAP activity in this
assay to be 0.2 OD units at 405 nanometers, when
it can be seen that the false negative rate was 1/16
(6%), and the false positive rate was 16/46 (35%).
The false negative result was in a patient who also
developed a raised serum alphafoetoprotein, and it
is possible that he had a mixed seminoma/teratoma
and relapsed with teratomatous disease. Of the 16
false positive patients, 15 were smokers (see Table
I). A repeat serum sample from the single non-
smoker with raised PLAP level (0.33 OD units)
revealed a fall to "normal levels" (0.11 OD units)
and the raised level was unexplained.
If only known non-smokers are analysed the
PLAP assay correctly diagnosed 8 out of 9 patients
with active seminoma (88%; 95% confidence
limits=47%-100%), and the assay correctly
diagnosed 21 of 22 disease-free patients (95%; 95%
confidence limits=76%-100%).
Six of 15 patients with a raised serum PLAP and
metastatic disease were smokers, and thus the cause
of the raised PLAP level was not unequivocal. In 5
of these cases the PLAP level fell following
treatment of the seminoma, despite no change in
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Figure 1 H17 E2 monoclonal antibody ILEA assay
for placental alkaline phosphatase like activity in the
serum of 62 patients with seminoma, either pre-
treatment or in remission. (For conversion of OD
units to International units see accompanying article
by Tucker et al. (1985) in this issue.)
Table I False positive PLAP assays: Correlation with smoking history.
Disease-free PLAP level Daily smoking
Stage Treatment period (months) (OD units at 405mm) history
I RT 32 1.12 40 Cigarettes
I RT 20 0.95 20 Cigarettes
I RT 35 0.85 30 Cigarettes
II CT 40 0.65 20 Cigarettes
IV CT 52 0.54 20 Cigarettes
I RT 20 0.52 40 Cigarettes
II RT 28 0.49 50 Cigarettes
I RT 18 0.48 10 Cigarettes
I RT 28 0.43 oz. Tobacco
I None 52 0.41 10 Cigarettes
II RT 40 0.40 10 Cigarettes
I RT 28 0.37 2 oz. Tobacco
I RT 26 0.33a Non-smoker
I RT 27 0.30 10 Cigarettes
I RT 23 0.23 20 Cigarettes
II CT 60 0.22 5 Cigars
aRepeat PLAP assay on this patient=0.11 OD Units.
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the pattern of smoking. The smoking history was
also available on 25 of the 30 disease-free patients
with low PLAP levels, and only 4 (16%) were
smokers. With regard to the possibility that these
30 cases with a low PLAP might be false negatives,
it must be acknowledged that with a follow-up in
this group of 18 to 54 months (mean 34 months)
some patients might relapse and thus had sublinical
disease at the time serum was taken for the PLAP
assay. The sensitivity of the assay to detect
subclinical seminoma has not been tested.
In 7 patients sequential serum samples were
assayed early during induction therapy allowing
comparison between serum levels of PLAP and the
clinical course. In all 7 patients disease regression
was correlated with a fall in PLAP level. Two
examples are shown (Figures 2 and 3) of which one
reveals squential correlations between serum PLAP
and an alternative marker in seminoma, viz., the
beta subunit of human chorionic gonadotrphin
(HCG), and another reveals the PLAP level rising
again before clinical evidence of relapse. In these
seven patients the initial rate of fall of PLAP varied
from a halving time of 92 to 26 days (median 13
days).
The case histories of two of these patients are as
follows:
Case 1 (Figure 2)
This 30-year-old man with a mediastinal pure seminoma
diagnosed at thoracotomy presented with cord
compression associated with extra dural tumour. He was
treated with four courses of combination chemotherapy
using cis-platinum etoposide and bleomycin (BEP)
(Peckham et al., 1983b) with rapid resolution of the
mediastinal mass and of signs of cord compression. He
remains in remission 3 years post chemotherapy. He was a
non-smoker. The serum PLAP level was 1.70 OD units on
two separate occasions, 5 days apart, before starting
chemotherapy but then regressed immediately after
chemotherapy with an approximate halving time of 11
days.
Case 2 (Figure 3)
This 31-year-old patient had pure seminoma diagnosed at
orchidectomy. The spermatic cord was involved with
tumour; lymphography and CT scanning demonstrated
abdominal node metastases measuring 5cm in cross-
sectional diameter. He was treated with 4 courses of
combination chemotherapy using the BEP regime; CT
scan then showed a small residual abdominal mass.
Because of clinical uncertainty about the significance of
this finding a further 2 courses of cis-platinum alone
(120mgm-2) were given. The patient remains well and the
CT scan findings unchanged over the last 12 months. He
was a non-smoker. It can be seen in Figure 3 that serum
levels of both PLAP and HCG rose on sequential assays
before chemotherapy and then regressed, with a halving
time for PLAP of -13 days. There was close correlation
between changes in serum levels of PLAP and of HCG.
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Figure 2 Placental alkaline phosphatase (PLAP) as a
tumour marker in Case 1, a patient with mediastinal
seminoma. I denotes the start of a chemotherapy
course (see text and also legend to Figure 1).
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Figure 3 Placental alkaline phosphatase (PLAP) as a
tumour marker in Case 2 (see text); a patient with
large volume abdominal metastases of testicular
seminoma. L denotes the start of each course of
chemotherapy. HCG=beta subunit of human
chorionic gonadotrophin. See also legend to Figure 1.
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Serum HCG levels were assayed by the
Department of Medical Oncology, Charing Cross
Hospital, London (Kardana & Bagshawe, 1976). Of
the 15 patients with metastatic seminoma and
raised PLAP levels, 3 had HCG levels > 10u -'
(1100ul-P, 224ul-1, 27ul-'). A further 3 patients
had serum HCG levels between 5 and 10ul-'.
Discussion
The results suggest that the serum level of PLAP
assayed by-the monoclonal antibody H17 E2 is a
useful marker for seminoma, especially in non-
smokers. It is noteworthy that other immunological
assays for PLAP detect raised levels in smokers
(Tonik et al., 1983; Maslow et al., 1983).
Elevated levels of PLAP were found in the great
majority of patients with metastatic seminoma
(15/16 (94%)) in this series; this represents a higher
sensitivity than that reported with a polyclonal
antiserum (Wahren et al., 1979; Lange et al., 1982)
and corresponds to the high incidence of PLAP
detectable on immunoperoxidase staining of
seminoma tissues (Uchida et al., 1981; Epenetos et
al., 1984).
The tumour markers alpha foeto protein (AFP)
and beta sub unit of human chorionic
gonadotrophin (HCG) have been shown to be
useful in the diagnosis and management of
malignant teratoma; however, their role in
seminoma is less clear. AFP is now believed to
derive from non-seminomatous components of the
disease. HCG may be associated with pure
seminoma; an elevated serum HCG level was found
in 14/29 (48.3%) of patients with Stage II, III & IV
seminoma reported from The Royal Marsden
Hospital (Ball et al., 1982).
The overall results of management of seminoma
are excellent (Peckham, 1981), and the role of
placental alkaline phosphatase as a tumour marker
has yet to be defined. Its use will be explored in the
diagnosis of primary and of recurrent disease and
in monitoring tumour response following surgery,
radiotherapy or chemotherapy. Additionally,
tumour tissue binding of the antibody can be
exploited both for analysis of histological specimens
(Epenetos et al., 1984), and by combination with an
appropriate isotope to attempt immunolocalisation
of metastatic disease (Jeppsson et al., 1984;
Epenetos et al., 1983).
The majority of patients with seminoma present
with clinical Stage I disease and a sensitive method
of assessment following orchidectomy may help to
define the need for radiotherapy to para-aortic and
pelvic lymph nodes, which at present constitutes
standard practice. In an analogous situation the
availability of good tumour markers for malignant
teratoma has led to the successful adoption of a
surveillance policy following orchidectomy for
clinical Stage I disease (Peckham et al., 1983a).
Small volume Stage II seminoma is controlled by
radiotherapy in 80 to 90% of cases (Peckham,
1981; Ball et al., 1982) and a tumour marker may
provide early detection of relapse and allow
monitoring of subsequent therapy.
In the management of advanced seminoma with
chemotherapy (Ball et al., 1982; Samuels &
Logothetis, 1983; Simon et al., 1983), a tumour
marker may be useful in a number of ways. The
pre-treatment level of the marker may have
prognostic significance as may the initial rate of fall
of marker following chemotherapy (Horwich &
Peckham, 1984). Change in the rate of marker
regression may be an early sign of drug resistance
and provide an indication for alternative
chemotherapy, and as with other stages, monitoring
of serum marker levels may detect relapse earlier
when retreatment is likely to be more effective.
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